Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated <i>MGMT</i> promoterMichael Lim, Antonio Omuro, Michael Weller et al.|Neuro-Oncology|2022Cited by 508
Multiplatform molecular analyses refine classification of gliomas arising in patients with neurofibromatosis type 1Calixto‐Hope G. Lucas, David A. Solomon, Ossama Maher et al.|Acta Neuropathologica|2022Cited by 50
Prospective genomically guided identification of “early/evolving” and “undersampled” IDH-wildtype glioblastoma leads to improved clinical outcomesYalan Zhang, David A. Solomon, Calixto‐Hope G. Lucas et al.|Neuro-Oncology|2022Cited by 31
CTIM-25. A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548Michael Weller, Antonio Omuro, Michael Lim et al.|Neuro-Oncology|2021Cited by 29
Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapyCalixto‐Hope G. Lucas, David A. Solomon, Sabine Mueller et al.|Neuro-Oncology|2021Cited by 27